Monoclonal antibody designed for SARS-nCoV-2 spike protein of receptor binding domain on antigenic targeted epitopes for inhibition to prevent viral entry

SARS, or severe acute respiratory syndrome, is caused by a novel coronavirus (COVID-19). This situation has compelled many pharmaceutical R&D companies and public health research sectors to focus their efforts on developing effective therapeutics. SARS-nCoV-2 was chosen as a protein spike to tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Abduljaleel, Zainularifeen, Shahzad, Naiyer, Aziz, Syed A., Malik, Shaheer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133318/
https://www.ncbi.nlm.nih.gov/pubmed/35616802
http://dx.doi.org/10.1007/s11030-022-10449-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133318/
https://www.ncbi.nlm.nih.gov/pubmed/35616802
http://dx.doi.org/10.1007/s11030-022-10449-x

Ejemplares similares